Honored for uncovering how mutations in the KRAS gene – present in more that 90% of pancreatic ductal adenocarcinomas – drive tumor growth. Once thought impossible to target, this discovery has paved the way to new therapies and brought renewed hope to patients and families worldwide.
Engineering Circuit-controlled T Cell Differentiation and Restructuring the Pancreatic Cancer Stroma to Optimize PDAC-targeted CAR T Cell Therapy for Clinical Translation
Creating next-generation CAR T cells that target both pancreatic tumors and their fibrotic stroma, using synthetic promoters to fine-tune T cell behavior, offering a promising new direction for pancreatic cancer immunotherapy.
Applying Artificial Intelligence to Electronic Health Records to Guide Pancreatic Cancer Screening
Utilizing large language models to analyze HER data and flag high-risk individuals for screening — embedding AI directly into hospital systems to enable scalable early detection.
Lysosomal Lipid Homeostasis is a Clinically Exploitable Vulnerability in KRAS-Inhibited Pancreatic Cancer
Targeting a unique metabolic vulnerability in KRAS-mutant tumors using clinically relevant drugs and synthetic lethality, with durable cures shown in preclinical models.
From Blood Sugar to Tumor Growth: How Diabetes Fuels Pancreatic Cancer Onset
Investigating how the sugar byproduct methylglyoxal leads to DNA mutations associated with pancreatic cancer and developing a novel blood-based screening tool.
Assessment of Pancreas Organ Health for Pancreatic Cancer Early Detection
Developing a multimodal platform that combines stool, blood, and CT imaging to detect pancreatic cancer before symptoms appear and leveraging changes in organ function as early warning signs.
Identification of Treatment-Associated Tumor Antigens for Targeted Immunotherapy in Pancreatic Cancer
Using mass spectrometry to identify new peptide antigens that emerge after KRAS inhibition, enabling novel vaccine and BiTE strategies that link targeted therapy with immunotherapy.
